Provide MOUD
overdose
Four (30.8 %) of the 13 sites dispensed methadone through their licensed methadone treatment program (OTP) in addition to providing BUP; 4 (30.8 %) sites also provided naltrexone to patients who were already being treated with naltrexone at the time they became pregnant. Eleven sites (84.6 %) provided both BUP-only (BUP mono) products and products combining BUP and naloxone (BUP/NX), while 1 site (7.7 %) provided only the BUP mono product and 1 site (7.7 %) provided only the BUP/NX product. Three sites (23.1 %) provided injectable BUP and 2 sites (15.4 %) provided implantable BUP. Two sites (15.4 %) dispensed BUP through their OTP while the remaining 11 (84.6 %) sites prescribed BUP in a non-OTP ambulatory/outpatient clinic setting. Most sites performed BUP induction by administering one or more initial doses in person (inpatient or in-clinic), with additional induction doses prescribed/dispensed for home administration. All sites provided patients with naloxone for overdose treatment, with 11 (84.6 %) providing access at the time of program admission; 6 (46.2 %) dispensed naloxone and 7 (53.8 %) provided prescriptions only. Six sites (46.2 %) also dispensed naloxone or provided prescriptions to family members and/or significant others.